NCT02127710 - A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 14, 2016

Study Completion Date

April 20, 2020

Conditions

Papillary Renal Cell Cancer

Interventions

DRUG

AZD6094

AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.

Trial Locations (23)

10021

Research Site, New York

19111

Research Site, Philadelphia

33916

Research Site, Fort Myers

35294

Research Site, Birmingham

37203

Research Site, Nashville

48201

Research Site, Detroit

52242

Research Site, Iowa City

60637

Research Site, Chicago

75246

Research Site, Dallas

77030

Research Site, Houston

91010

Research Site, Duarte

94305

Research Site, Palo Alto

02215

Research Site, Boston

T2N 4N2

Research Site, Calgary

T6G 1Z2

Research Site, Edmonton

M4N 3M5

Research Site, Toronto

M5G 2M9

Research Site, Toronto

08041

Research Site, Barcelona

CB2 0QQ

Research Site, Cambridge

G12 OYN

Research Site, Glasgow

EC1M 6BQ

Research Site, London

W1G 6AD

Research Site, London

M20 4BX

Research Site, Manchester